论文部分内容阅读
伊布利特是一种Ⅲ类抗心律失常药,主要用于心房颤动或扑动。伊布利特的严重不良反应之一为心律失常,表现为QT间期延长和尖端扭转性室性心动过速(TdP)。TdP一般发生于用药后1h内。伊布利特引致TdP的机制可能和复极异常有关。防治伊布利特所致心律失常措施如下:一旦出现心律失常应立即停药,电击复律,给予异丙肾上腺素、阿托品,补钾和镁,并可给予β受体阻滞剂;电解质异常患者用药前应纠正电解质;伊布利特应避免和其他抗心律失常药联用;用药期间宜进行心电监测;女性患者应用伊布利特比男性易出现心律失常,应予注意。
Ibutilide is a type III antiarrhythmic drug that is mainly used for atrial fibrillation or flutter. One of the major adverse events of ibutilide is arrhythmia, manifested by prolonged QT intervals and torsades de pointes (TdP). TdP generally occurs within 1h after treatment. The mechanism by which ibutilide causes TdP may be related to repolarization abnormalities. Prevention and treatment of arrhythmia caused by ibutilide are as follows: In the event of arrhythmia should be immediately discontinued, cardioversion, given isoproterenol, atropine, potassium and magnesium, and may be given β blockers; electrolyte abnormalities Patients should be corrected before using electrolyte; ibutilide should be avoided and other anti-arrhythmic drug combination; medication should be monitored during the ECG; female patients with ibuprofen than men prone to arrhythmia, should be noted.